Reported 4 months ago
Novo Nordisk's stock surged over 5% in premarket trading after the company exceeded Wall Street's profit expectations for Q1, reporting $11.9 billion in revenue and $0.99 adjusted EPS despite a slight reduction in its 2025 sales outlook. While sales of its popular GLP-1 drugs increased by 13% year-over-year, Wegovy sales fell short of expectations, putting pressure on its market share against competitors like Eli Lilly. CEO Lars Fruergaard Jørgensen indicated that Novo still holds a dominant 72% of the global obesity and diabetes GLP-1 market.
Source: YAHOO